The White House Office of Science and Technology Policy on Tuesday released its long-awaited policy plans for overseeing ...

On May 16 in New York, Endpoints News and the Financial Times are teaming up to host the US Pharma and Biotech Summit. I’ve ...

High medical costs ate away at the profits of big Medicare Advantage insurers CVS Health and Humana in the first quarter of ...

Walking Fish Therapeutics, a biotech startup that attempted to create engineered B cell therapies, has shuttered, founder Rusty Williams confirmed to Endpoints News. The South San Francisco ...

Madrigal Pharmaceuticals is “making great progress” on the rollout of its NASH drug Rezdiffra, executives said less than a month post-launch. Rezdiffra was approved in March as the first treatment for ...

House Oversight Committee Chair James Comer (R-KY) is pressing the FDA to share more information on its presence in China amid growing concerns on Capitol Hill about Chinese involvement in biotech and ...

Last week, we made the decision to shut down Endpoints MarketingRx. Over the last year, Endpoints News has put more resources into our core biopharma and healthcare coverage, and into work where we’re ...

Eli Lilly will face questions from a panel of Alzheimer's experts on June 10, setting up an approval decision for donanemab after a surprise delay by the FDA in early March. The drug will go before ...

In the bid to lock up patent rights to a growing suite of gene-editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the ...

Transcarent’s $126 million Series D round, which in May bumped its valuation to $2.2 billion, stands apart from most growth-stage, high-valuation startups that haven't raised capital in the past few ...

In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us, ...

Illumina prefers to spin off Grail into an independent business rather than selling the cancer diagnostics company, according to a financial document released Monday that describes the Illumina ...